Celularity Inc

GX Acquisition Corp (Nasdaq: GXGX), sponsored by GX Clarke & Co., completed its SPAC IPO in 2018 targeting the healthcare and life sciences sector. The vehicle filed a Form 10-Q on May 15, 2020, covering quarterly operations ahead of its announced business combination with Celularity Inc., a clinical-stage biotechnology company focused on placental-derived cell therapies and allogeneic cellular medicines. At the time of filing, the SPAC was in its combination phase, with the Celularity transaction representing a high-profile entry into the regenerative medicine and cell therapy space. Sign up for SpacDesk to access the full filing history, deal timeline, and sponsor data for GXGX and hundreds of other SPACs.